T1	Participants 117 261	To evaluate the safety and efficacy of 0.59-mg and 2.1-mg fluocinolone acetonide (FA) intravitreous implants in noninfectious posterior uveitis.
T2	Participants 341 445	0.59-mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients
T3	Participants 521 569	Uveitis recurrence was reduced in implanted eyes
T4	Participants 720 738	0.59-mg dose group
T5	Participants 801 822	the 2.1-mg dose group
T6	Participants 834 876	More implanted eyes than nonimplanted eyes
T7	Participants 915 985	Implanted eyes had higher incidences of intraocular pressure elevation
T8	Participants 1135 1237	Cataracts were extracted in 93% of phakic implanted eyes vs 20% of phakic nonimplanted eyes (P < .01).
T9	Participants 1350 1395	subjects with noninfectious posterior uveitis
T10	Participants 1447 1516	significant proportion required intraocular pressure-lowering surgery
T11	Participants 1636 1670	in noninfectious posterior uveitis
